CASP8 and cancer: Since proteasome inhibitors such as bortezomib and carfilzomib are nowadays commonly used as anti-cancer therapeutics [13], we here set out to obtain mechanistic insight into the process of caspase-8 activation, as well as its regulation and relevance for apoptosis susceptibility under conditions of proteasome inhibition.